Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 3/20 | 0.46 |
| ▸ | MAPKAPK2 | P49137 | 5/20 | 0.42 |
| ▸ | CYP11B2 | P19099 | 5/20 | 0.39 |
| ▸ | ICMT | O60725 | 1/20 | 0.39 |
| ▸ | GRM5 | P41594 | 1/20 | 0.38 |
| ▸ | GRM1 | Q13255 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4400768 | 0.79 | ALDH1A1 (0.56) | CYP19A1MAPKAPK2ICMTGRM5 | |
| SCHEMBL14975562 | 0.75 | CYP3A4 (0.49) | — | |
| SCHEMBL17630186 | 0.75 | ADH5 (0.54) | CYP19A1MAPKAPK2ICMTGRM5 | |
| SCHEMBL27325095 | 0.75 | PDE4A (0.45) | CYP19A1MAPKAPK2CYP11B2ICMTGRM5 | |
| SCHEMBL27303560 | 0.75 | CYP19A1 (0.43) | CYP19A1MAPKAPK2CYP11B2ICMTKDM4E | |
| SCHEMBL6435888 | 0.73 | CYP19A1 (0.42) | CYP19A1MAPKAPK2CYP11B2ICMTGRM1 | |
| SCHEMBL8694857 | 0.73 | MAPKAPK2 (0.50) | CYP19A1MAPKAPK2 | |
| SCHEMBL19651232 | 0.73 | NR4A1 (0.42) | CYP19A1MAPKAPK2CYP11B2GRM1 | |
| Lithium Ion SCHEMBL19639780 | 0.72 | CA1 (0.46) | CYP19A1MAPKAPK2CYP11B2ICMTGRM1 | |
| SCHEMBL27311533 | 0.72 | MAPKAPK2 (0.52) | CYP19A1MAPKAPK2CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109311850-B | Imidazolone compounds as human neutrophil elastase inhibitors | 奇斯药制品公司 | 2021-11-19 | — | — | CN | disclosed |
| EP-3464273-B9 | IMIDAZOLONE COMPOUNDS AS HUMAN NEUTROPHIL ELASTASE INHIBITORS | CHIESI FARM SPA (IT) | 2020-10-21 | — | — | EP | disclosed |
| EP-3464273-B9 | IMIDAZOLONE COMPOUNDS AS HUMAN NEUTROPHIL ELASTASE INHIBITORS | CHIESI FARM SPA (IT) | 2020-10-21 | — | — | EP | disclosed |
| EP-3464273-B1 | IMIDAZOLONE COMPOUNDS AS HUMAN NEUTROPHIL ELASTASE INHIBITORS | CHIESI FARM SPA (IT) | 2020-04-08 | — | — | EP | disclosed |
| EP-3464273-B1 | IMIDAZOLONE COMPOUNDS AS HUMAN NEUTROPHIL ELASTASE INHIBITORS | CHIESI FARM SPA (IT) | 2020-04-08 | — | — | EP | disclosed |
| EP-3464269-B1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF A HNE RELATED DISEASE | CHIESI FARM SPA (IT) | 2020-04-01 | — | — | EP | disclosed |
| EP-3464273-A1 | IMIDAZOLONE COMPOUNDS AS HUMAN NEUTROPHIL ELASTASE INHIBITORS | Chiesi Farmaceutici S.p.A. (IT) | 2019-04-10 | — | — | EP | disclosed |
| EP-3464269-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF A DISEASE IN WHICH HNE IS IMPLICATED | Chiesi Farmaceutici S.p.A. (IT) | 2019-04-10 | — | — | EP | disclosed |
| EP-3233833-B1 | NOVEL COMPOUNDS | CHIESI FARM SPA (IT) | 2019-02-20 | — | — | EP | disclosed |
| EP-3233833-B1 | NOVEL COMPOUNDS | CHIESI FARM SPA (IT) | 2019-02-20 | — | — | EP | disclosed |
| US-20170342056-A1 | NOVEL COMPOUNDS | CHIESI FARMACEUTICI S.P.A. (IT) | 2017-11-30 | — | — | US | disclosed |
| US-9802919-B1 | Compounds | CHIESI FARMACEUTICI S.P.A. (IT) | 2017-10-31 | — | — | US | disclosed |
| US-9802919-B1 | Compounds | CHIESI FARMACEUTICI S.P.A. (IT) | 2017-10-31 | — | — | US | disclosed |
| EP-3233833-A1 | NOVEL COMPOUNDS | Chiesi Farmaceutici S.p.A. (IT) | 2017-10-25 | — | — | EP | disclosed |
| US-9409870-B2 | Compounds | CHIESI FARMACEUTICI S.P.A. (IT) | 2016-08-09 | — | — | US | disclosed |
| US-9409870-B2 | Compounds | CHIESI FARMACEUTICI S.P.A. (IT) | 2016-08-09 | — | — | US | disclosed |
| WO-2016096638-A1 | NOVEL COMPOUNDS | CHIESI FARMACEUTICI S.P.A. (IT) | 2016-06-23 | — | — | WO | disclosed |
| WO-2016096638-A1 | NOVEL COMPOUNDS | CHIESI FARMACEUTICI S.P.A. (IT) | 2016-06-23 | — | — | WO | disclosed |
| US-20160168101-A1 | NOVEL COMPOUNDS | CHIESI FARMACEUTICI S.P.A. (IT) | 2016-06-16 | — | — | US | disclosed |
| US-20160168101-A1 | NOVEL COMPOUNDS | CHIESI FARMACEUTICI S.P.A. (IT) | 2016-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170342056-A1 | NOVEL COMPOUNDS | SERPINB1, ELANE, MPO | CYP19A1 3162/4885MAPKAPK2 2711/4885CYP11B2 401/4885 |
| US-20160168101-A1 | NOVEL COMPOUNDS | ELANE, SERPINB1, MPO | CYP19A1 3266/4885MAPKAPK2 2666/4885CYP11B2 527/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.